Table 7 Impact of C1orf63 expression on OS in different groups of breast cancer patients. 182 patients were divided according to either TNM stage or PR expression. There were 74 patients with TNM I ~ II stages, 107 patients with TNM III ~ IV stages, 74 patients with PR positive expression and 107 patients with PR negative expression. The differences of OS rates were tested using the Kaplan–Meier method with log rank test
Group | C1orf63 expression | Patients | Events | OS rate (%)b | P (log-rank) | |
|---|---|---|---|---|---|---|
3-year (95Â % CI)c | 5-year (95Â % CI)c | |||||
TNM stages (I ~ II) | Negative | 58 | 7 | 94.5 (88.4, 100.0) | 83.4 (71.6, 95.2) | 0.432 |
| Â | Positive | 16 | 2 | 87.5 (71.2, 100.0) | 87.5 (71.2, 100.0) | Â |
TNM stages (III ~ IV) | Negative | 80 | 43 | 58.0 (46.8, 69.2) | 46.2 (33.9, 58.5) | 0.036 |
| Â | Positive | 27 | 6 | 80.0 (64.3, 95.7) | 72.7 (53.1, 92.3) | Â |
PR positive | Negative | 50 | 16 | 87.2 (77.6, 96.8) | 70.0 (55.5, 84.5) | 0.106 |
| Â | Positive | 22 | 1 | 100a | 83.3 (53.5, 100.0) | Â |
PR negative | Negative | 85 | 32 | 65.8 (55.4, 76.2) | 62.1 (51.1, 73.1) | 0.906 |
| Â | Positive | 22 | 7 | 65.0 (44.0, 86.0) | 65.0 (44.0, 86.0) | Â |